Document:

EX-4.5

 Exhibit 4.5 

 
 

 
 THIS WARRANT AND THE SECURITIES ISSUABLE UPON EXERCISE HEREUNDER HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF
1933 AS AMENDED (the “1933 ACT”), OR ANY STATE SECURITIES LAWS. THEY MAY NOT BE SOLD, OFFERED FOR SALE, PLEDGED, OR HYPOTHECATED IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT RELATED THERETO OR AN OPINION OF COUNSEL REASONABLY
SATISFACTORY TO YOU THAT SUCH REGISTRATION IS NOT REQUIRED UNDER THE 1933 ACT, OR ANY APPLICABLE STATE SECURITIES LAWS. 

PLAIN ENGLISH WARRANT AGREEMENT 
 This is a PLAIN ENGLISH WARRANT AGREEMENT dated May 13, 2013 by and between VIOLIN MEMORY, INC., a Delaware corporation, and TRIPLEPOINT CAPITAL LLC, a Delaware limited liability
company. 
 The words “We”, “Us”, or “Our” refer to the warrant holder, which is TRIPLEPOINT CAPITAL LLC. The
words “You” or “Your” refers to the issuer, which is VIOLIN MEMORY, INC., and not to any individual. The words “the Parties” refers to both TRIPLEPOINT CAPITAL LLC and VIOLIN MEMORY, INC. This Plain English Warrant
Agreement may be referred to as the “Warrant Agreement”. 
 The Parties have entered into a Plain English Growth Capital Loan and
Security Agreement dated as of May 13, 2013, the “Loan Agreement”. 
 In consideration of such Loan Agreement, the Parties agree
to the following mutual agreements and conditions set forth below: 
 WARRANT INFORMATION

  

					
	 Effective Date
	 	 Warrant Number
	 	 Loan Facility Number

	 May 13, 2013
	 	0803-W-01	 	0803-GC-01; 0803-GC-02

  

							
	 Warrant Coverage
	 	 Number of Shares
	 	 Price Per Share
	 	 Type of Stock

	Part 1: Up to $2,025,000 (4.5% of $10,000,000; 5.25% of $30,000,000), as set forth below.	 	Part 1: 75,000; up to an additional 262,500, as set forth below.	 	$6.00	 	Series D Preferred Stock
	Part 2: Up to $300,000 (3% of $10,000,000), subject to reduction as set forth below.	 	Part 2: Up to 50,000, as set forth below.	 		 	

 OUR CONTACT INFORMATION 

 

					
	 Name
	 	 Address For Notices
	 	 Contact Person

	 TriplePoint Capital LLC
	 	 2755 Sand Hill Road, Ste. 150
 Menlo Park, CA 94025
 Tel: (650) 854-2090

Fax: (650) 854-1850
	 	 Sajal Srivastava, COO
 Tel: (650) 233-2102
 Fax: (650) 854-1850

email: legal@triplepointcapital.com

 YOUR CONTACT INFORMATION 

 

					
	 Customer Name
	 	 Address For Notices
	 	 Contact Person

	 Violin Memory, Inc.
	 	 685 Clyde Avenue
 Mountain View, CA 94043
	 	 Cory Sindelar, CFO
 Tel: 650-396-1698
 email: csindelar@vmem.com

  
 1 

  

	1.	WHAT YOU AGREE TO GRANT US 

  

Part 1: You grant to Us and We are entitled, upon the terms and subject to the conditions set forth in this Warrant Agreement, to purchase from
You, at a price per share equal to the Exercise Price, that number of fully paid and non-assessable shares of Your Warrant Stock equal to Four Hundred Fifty Thousand Dollars ($450,000), divided by the Exercise Price. 

In addition, You grant to Us and We are entitled, upon the terms and subject to the conditions set forth in this Warrant Agreement, to purchase from You,
at a price per share equal to the Exercise Price, an additional number of fully paid and non-assessable shares of Your Warrant Stock equal to 5.25% of any amounts advanced under the Part 1 Commitment Amount of the Loan Agreement in excess of
$10,000,000, divided by the Exercise Price. 
 Part 2: Upon the availability of Part 2 Commitment Amount under the Loan Agreement, You
grant to Us and We are entitled, upon the terms and subject to the conditions set forth in this Warrant Agreement, to purchase from You, at a price per share equal to the Exercise Price, an additional number of fully paid and non-assessable shares
of Your Warrant Stock equal to 3.0% of any amounts advanced under the Part 2 Commitment Amount of the Loan Agreement, divided by the Exercise Price. Notwithstanding the foregoing, in the event You have maintained, as of any time, two consecutive
fiscal quarters of positive cash flow, subject to Our satisfactory confirmation, then the Part 2 Warrant Coverage shall be reduced to Zero Dollars ($0), effective as of the end of the second consecutive fiscal quarters of positive cash flow.

 The number of shares of Warrant Stock and the Exercise Price of such Warrant Stock are subject to adjustment as provided in Section 4
hereof. 
 For purposes of this Warrant Agreement, the following capitalized terms have the meanings given below: 

“Exercise Price” means $6.00. 
 “Warrant Stock” means Your Series D Preferred Stock. 
 The Parties agree that this
Warrant Agreement to purchase the Warrant Stock has a fair market value equal to $100 and that $100 of the issue price of the investment will be allocable to the Warrant Agreement and the balance shall be allocable to the Loan Agreement for income
tax purposes and the original issue discount on the Loan Agreement shall be considered to be zero. 
  

 

	2.	WHEN ARE WE ENTITLED TO PURCHASE YOUR WARRANT STOCK. 

 
 The term of this Warrant Agreement and our right
to purchase Warrant Stock will begin the Effective Date, and shall be available through and including May 13, 2017. 
 Notwithstanding the
foregoing, Our right to purchase the Warrant Stock shall be automatically and fully exercised via the net issuance method described below (without surrender of the Warrant Agreement) upon the occurrence of a Merger Event, as defined below, with a
Person that is not one of Your affiliates, in which Your capital stock is exchanged for (i) solely for cash or (ii) any combination of cash and stock that is traded on a recognized public exchange or on the NASDAQ National Market where the
combined value of such cash and stock equates to a total per share consideration equal to or greater than two (2) times the aggregate Exercise Price. No less than ten (10) business days prior to any Merger Event, You shall provide Us with
written notice of the proposed Merger Event together with, to the extent available or existing, a copy of the executed merger agreement, or other definitive documentation (and all schedules and exhibits thereto) and information concerning Your
expected capitalization immediately prior to the Merger Event. Upon consummation of the Merger Event, You shall promptly provide Us with (a) a copy of any modifications or amendments to the executed merger agreement (or an executed merger
agreement to the extent not previously provided), (b) any other applicable documents in connection therewith, (c) updated information, if any, concerning Your capitalization immediately prior to the Merger Event, and, (d) upon
request, by Us any other information reasonably necessary to an informed evaluation of Our rights under this Agreement. 

  
 2 

  

	3.	HOW WE MAY PURCHASE YOUR WARRANT STOCK. 

 
 We may exercise Our purchase rights, in whole or
in part, at any time, or from time to time, prior to the expiration of the term of this Warrant Agreement, by giving You a completed and executed Notice of Exercise in the form attached as Exhibit I. Promptly upon receipt of the
Notice of Exercise and in any event no later than twenty-one (21) days after you have received Our Notice of Exercise and payment of the aggregate Exercise Price for the shares purchased, You will issue to Us a certificate for the number of
shares of Warrant Stock that We have purchased and You will execute the Acknowledgment of Exercise in the form attached hereto as Exhibit II indicating the number of shares which will be available to Us for future
purchases, if any. 
 We may pay for the Warrant Stock by either (i) cash or check, or (ii) by the net issuance method as
determined below. If We elect the Net Issuance method, You will issue Warrant Stock using the following formula: 
  

					
				  	 X = Y(A-B)

           A

		
	 	Where: X =	  	  	the number of shares of Warrant Stock to be issued to Us.
	 	Y =	  	  	the number of shares of Warrant Stock We request to be exercised under this Warrant Agreement.
	 	A =	  	  	the fair market value of one share of Warrant Stock.
	 	B =	  	  	the Exercise Price.

 For purposes of the above calculation, current fair market value of Warrant Stock shall mean with respect to each share
of Warrant Stock: 
 If the exercise is in connection with the initial public offering of Your Common Stock, and if Your registration
statement relating to such public offering has been declared effective by the SEC, then the fair market value per share shall be the product of (x) the initial “Price to Public” specified in the final prospectus of the offering and
(y) the number of shares of Common Stock into which each share of Warrant Stock is convertible at the time of such exercise; 
 If this
Warrant Agreement is exercised after, and not in connection with, Your initial public offering, and: 
  

	 	•	 	 if traded on a securities exchange, the fair market value shall be the product of (x) the average of the closing prices over a five (5) day
period ending three (3) days before the day the current fair market value of the securities is being determined and (y) the number of shares of Common Stock into which each share of Warrant Stock is convertible at the time of such
exercise; or 

  

	 	•	 	 if actively traded over-the-counter, the fair market value shall be the product of (x) the average of the closing bid and asked prices quoted on
the NASDAQ system (or similar system) over the five (5) day period ending three (3) days before the day the current fair market value of the securities is being determined and (y) the number of shares of Common Stock into which each
share of Warrant Stock is convertible at the time of such exercise. 

 If this Warrant Agreement is exercised prior to or
after Your initial public offering, and: 
  

	 	•	 	 Your Common Stock is not listed on any securities exchange or quoted in the NASDAQ System or the over-the-counter market, the current fair market value
of Warrant Stock shall be the product of (x) the fair market value of a share of Your Common Stock set forth in Your latest 409A Valuation Report), as determined in good faith by Your Board of Directors and (y) the number of shares of
Common Stock into which each share of Warrant Stock is convertible at the time of such exercise, unless You shall become subject to a merger, acquisition or other consolidation pursuant to which You are not the surviving party, in which case the
fair market value of Warrant Stock shall be deemed to be the value received by the holders of Your Warrant Stock on a common equivalent basis pursuant to such merger or acquisition or other consolidation. 

During the term of this Warrant Agreement, You will at all times from and after the Effective Date have authorized and reserved a sufficient number of
shares of (a) Warrant Stock to provide for the exercise of our rights to purchase Warrant Stock, and (b) Common Stock to provide for the conversion of the Warrant Stock. 

  
 3 

 If We elect to exercise part of the Warrant Agreement, You will promptly issue to Us an amended Warrant
Agreement stating the remaining number of shares that are available. All other terms and conditions of that amended Warrant Agreement shall be identical to those contained in this Warrant Agreement. 

If at the end of the term of this Warrant Agreement or upon the consummation of a Merger Event contemplated by Section 2 above, the fair market
value of one share of Warrant Stock (or other security issuable upon the exercise hereof) as determined in accordance herewith is greater than the Exercise Price in effect on such date, then this Warrant Agreement shall automatically be deemed on
and as of the date of such termination or Merger Event (as applicable) to be converted pursuant hereto as to all shares of Warrant Stock (or such other securities or consideration) for which it shall not previously have been exercised or converted,
and You shall promptly deliver a certificate representing the shares of Warrant Stock (or such other securities or consideration) issued upon such conversion to Us. If at the end of the term of this Warrant Agreement or upon the consummation of a
Merger Event contemplated by Section 2 above, the fair market value of one share of Warrant Stock (or other security issuable upon the exercise hereof) as determined in accordance herewith is less than the Exercise Price in effect on such date,
then this Warrant Agreement shall automatically terminate and be of no further force or effect. 
  

 

	4.	WHEN WILL THE NUMBER OF SHARES AND EXERCISE PRICE CHANGE. 

 
  

	 	•	 	 If You are Acquired. Subject to Section 2 above, if at any time: (i) there is a reorganization of Your stock (other than a
reclassification, exchange or subdivision of Your stock otherwise provided for in this Warrant Agreement); (ii) You merge or consolidate with or into another entity, whether or not You are the surviving entity; (iii) You sell or convey, or
grant an exclusive license with respect to, all or substantially all of Your assets to any other person; or (iv) there occurs any transaction or series of related transactions that result in the transfer of fifty percent (50%) or more of
the outstanding voting power of the capital stock of You (each of the foregoing events are referred to as a “Merger Event”), then, as a part of such Merger Event, lawful provision shall be made so that We shall thereafter be entitled to
receive, upon exercise of Our rights under this Warrant Agreement, the number of shares of preferred stock or other securities of the successor or surviving person resulting from such Merger Event, equal in value to that which would have been
issuable if We had exercised Our rights under this Warrant Agreement immediately prior to the Merger Event. In any such case, appropriate adjustment (as determined in good faith by Your Board of Directors) shall be made in the application of the
provisions of this Warrant Agreement with respect to Our rights and interest after the Merger Event so that the provisions of this Warrant Agreement (including adjustments of the Exercise Price and number of shares of Warrant Stock purchasable)
shall be applicable to the greatest extent possible. 

  

	 	•	 	 If You Reclassify Your Stock. If at any time You combine, reclassify, exchange or subdivide Your securities or otherwise, change any of the
securities as to which purchase rights under this Warrant Agreement exist into the same or a different number of securities of any other class or classes, this Warrant Agreement will thereafter represent the right to acquire such number and kind of
securities as would have been issuable as the result of such change with respect to the securities which were subject to the purchase rights under this Warrant Agreement immediately prior to such combination, reclassification, exchange, subdivision
or other change. 

  

	 	•	 	 If You Subdivide or Combine Your Shares or if Your Series D Preferred Stock is Converted to Common Stock. If at any time You combine or
subdivide Your Series D Preferred Stock, the Exercise Price will be proportionately decreased in the case of a subdivision, or proportionately increased in the case of a combination. If at any time, all shares of Your Series D Preferred Stock are
converted into shares of Your Common Stock, this Warrant Agreement shall become exercisable for that number of shares of Your Common Stock issuable upon conversion of that number of shares of Series D Preferred Stock for which this Warrant Agreement
was exercisable as of the date of such conversion, and the Exercise Price will be proportionately adjusted such that the aggregate Exercise Price for all such shares shall remain constant; thereafter, “Warrant Stock” shall refer to Your
Common Stock. 

  

	 	•	 	 If You Pay Stock Dividends. If at any time You pay a dividend payable in, or make any other distribution (except any distribution specifically
provided for in the above paragraphs) of Your Series D Preferred Stock, then the Exercise Price shall be adjusted, from and after the record date of such dividend or distribution, to that price determined by multiplying the Exercise Price in effect
immediately prior to such record date by a fraction (i) the numerator of which shall be the total number of all shares of Your Series D Preferred Stock outstanding immediately prior to such dividend or distribution, and (ii) the
denominator of which shall be the total number of all shares of Your Series D Preferred Stock outstanding immediately after such dividend or distribution. We will thereafter be entitled to purchase, at the Exercise Price resulting from such
adjustment, the number of shares of Warrant Stock (calculated to 

  
 4 

	 	 
the nearest whole share) obtained by multiplying the Exercise Price in effect immediately prior to such adjustment by the number of shares of Warrant Stock issuable upon the exercise hereof
immediately prior to such adjustment and dividing the product thereof by the Exercise Price resulting from such adjustment. 

  

	 	•	 	 If You Change the Antidilution Rights of the Warrant Stock or Issue New Preferred or Convertible Stock. All antidilution rights applicable to
the Warrant Stock purchasable under this Warrant Agreement are as set forth in Your Certificate of Incorporation, as amended through the Effective Date. You will promptly provide Us with any restatement, amendment, modification of or waiver of any
right under Your Certificate of Incorporation. You will provide Us with written notice of any issuance of Your stock or other equity security to occur after the Effective Date (other than issuances of stock or equity securities pursuant to customary
employee stock plans or sales of Series D Preferred Stock at a price at or above $6.00 per share) that results in the adjustment of anti-dilution rights applicable to the Warrant Stock under your Certificate of Incorporation, which notice shall
include (a) the price at which such stock or security is to be sold, (b) the number of shares to be issued, and (c) such other information as necessary for Us to determine if a dilutive event has occurred or will occur as a result of
such issuance. 

  
  

	5.	WE CAN TRANSFER THIS PLAIN ENGLISH WARRANT AGREEMENT. 

 
 Subject to the terms and conditions contained in
Section 7 and Your prior receipt of a written instrument executed by the transferee agreeing to bound by all the obligations hereunder (including those set forth in Section 7), We (or any successor transferee) may transfer in whole or in
part this Warrant Agreement and all its rights (other than any rights to receive information from You under Section 9 hereof). You will record the transfer on Your books when You receive Our Notice of Transfer in the form attached hereto as
Exhibit III, Our payment of all transfer taxes and other governmental charges involved in such transfer, and the aforementioned written instrument. 
  

 

	6.	REPRESENTATIONS, WARRANTIES, AND COVENANTS FROM YOU. 

 
  

	 	•	 	 Reservation of Warrant Stock. The Warrant Stock issuable upon exercise of Our rights under this Warrant Agreement will be duly and validly
reserved and when issued in accordance with the provisions of this Warrant Agreement will be validly issued, fully paid and non-assessable, and will be free of any taxes, liens, charges or encumbrances of any nature whatsoever; provided, however,
that the Warrant Stock issuable pursuant to this Warrant Agreement may be subject to restrictions on transfer under state and/or Federal securities laws. Upon Our exercise, You will issue to Us certificates for shares of Warrant Stock without
charging Us any tax, or other cost incurred by You in connection with such exercise and the related issuance of shares of Warrant Stock. You will not be required to pay any tax, which may be payable in respect of any transfer involved and the
issuance and delivery of any certificate in a name other than TriplePoint Capital LLC. 

  

	 	•	 	 Due Authority. Your execution and delivery of this Warrant Agreement and the performance of Your obligations hereunder, including the issuance
to Us of the right to acquire the shares of Warrant Stock, have been duly authorized by all necessary corporate action on Your part and this Warrant Agreement is not inconsistent with Your Certificate of Incorporation or Bylaws, does not contravene
any law or governmental rule, regulation or order applicable to it, do not and will not contravene any provision of, or constitute a default under, any indenture, mortgage, material contract or other instrument to which You are a party or by which
You are bound, and this Warrant Agreement constitutes a legal, valid and binding agreement, enforceable in accordance with its respective terms, subject to laws of general application relating to bankruptcy, insolvency and the relief of debtors and
the rules of law or principles at equity governing specific performance, injunctive relief and other equitable remedies. 

  

	 	•	 	 Consents and Approvals. No consent or approval of, giving of notice to, registration with, or taking of any other action in respect of any
state, Federal or other governmental authority or agency is required with respect to execution, delivery and Your performance of Your obligations under this Warrant Agreement, except for the filing of any required notices pursuant to Federal and
state securities laws, which filings will be effective by the times required thereby. 

  

	 	•	 	 Issued Securities. All of Your issued and outstanding shares of Common Stock, Warrant Stock or any other securities have been duly authorized
and validly issued and are fully paid and nonassessable. All outstanding shares of Common Stock and Warrant Stock were issued in full compliance with all Federal and state securities laws. In addition as of the Effective Date:

  
 5 

 Your authorized capital as of the Effective Date consists of (A) 250,000,000 shares of Common Stock, of
which 31,356,143 shares of Common Stock are issued and outstanding, and (B) 111,000,000 shares of preferred stock, of which 93,617,015 shares are issued and outstanding. 
 You have reserved 67,000,000 shares of Common Stock for issuance under Your Stock Incentive Plan, under which an aggregate of 31,872,277 options and restricted stock units are outstanding as of the
Effective Date and 28,353,821 shares of Common Stock are outstanding (and included in prior paragraph). Except as otherwise provided in this Warrant Agreement, as noted above and that certain Warrant to Purchase Series D Preferred Stock of the
Company issued to Toshiba America Electronic Components, Inc. on December 22, 2011, there are, as of the Effective Date, no other options, warrants, conversion privileges or other rights presently outstanding to purchase or otherwise acquire
any authorized but unissued shares of Your capital stock or other of Your securities. 
 As of the Effective Date, except as set forth in Your
Investors’ Rights Agreement, a true, correct and complete copy of which has been delivered to Us prior to the issuance of this Warrant, and letter agreements with certain of your stockholders granting the ability to participate in the
preemptive rights set forth in such Investors’ Rights Agreement notwithstanding the number of shares held by such stockholders, Your stockholders do not have preemptive rights to purchase new issuances of Your capital stock. 

 

	 	•	 	 Other Commitments to Register Securities. As of the Effective Date, except as set forth in this Warrant Agreement and the Investors’ Rights
Agreement, You are not, pursuant to the terms of any other agreement currently in existence, under any obligation to register under the 1933 Act any of Your presently outstanding securities or any of Your securities which may hereafter be issued.

  

	 	•	 	 Exempt Transaction. Subject to the accuracy of Our representations in Section 7 hereof, the issuance of the Warrant Stock upon exercise of
this Warrant Agreement will constitute a transaction exempt from (i) the registration requirements of Section 5 of the 1933 Act, in reliance upon Section 4(2) thereof, and (ii) the qualification requirements of the applicable
state securities laws. 

  

	 	•	 	 Compliance with Rule 144. We may sell the Warrant Stock issuable hereunder in compliance with Rule 144 promulgated by the Securities and
Exchange Commission. Within ten (10) days of Our request, You agree to furnish Us, a written statement confirming Your compliance with the filing requirements of the Securities and Exchange Commission as set forth in such Rule 144, as may be
amended. 

  

	 	•	 	 No Impairment. You agree not to, by amendment of Your Certificate of Incorporation, by-laws or other organizational or charter documents or
through a reorganization, transfer of assets, consolidation, merger, dissolution, issue or sale of securities or any other voluntary action, avoid or seek to avoid the observance or performance of any of the terms to be observed or performed under
this Warrant by You, but shall at all times in good faith assist in carrying out of all the provisions of this Warrant and in taking all such action as may be necessary or appropriate to protect Our rights under this Warrant against impairment.
However, You shall not be deemed to have impaired Our rights if You amend Your Certificate of Incorporation, or the holders of Your preferred stock exercise or waive their rights thereunder, in a manner that does not (individually or when considered
in the context of any other actions being taken in connection with such amendments or waivers) affect Us in a manner different from the effect that such amendments or waivers have on the rights of other holders of the same series and class as the
Warrant Stock (assuming Our exercise of the Warrant Agreement); provided, however, that, notwithstanding the foregoing, You shall not impose any restrictions on the transferability or alienability of the Warrant Stock other than in
effect as of the Effective Date without the express written consent of Us. 

  

 

	7.	OUR REPRESENTATIONS AND COVENANTS TO YOU. 

 
  

	 	•	 	 Investment Purpose. The right to acquire Warrant Stock or the Warrant Stock issuable upon exercise of Our rights contained herein and the Common
Stock issuable upon conversion will be acquired for investment purposes and not with a view to the sale or distribution of any part thereof, and We have no present intention of selling or engaging in any public distribution of the same in violation
of the 1933 Act. 

  

	 	•	 	 Private Issue. We understand (i) that this Warrant Agreement, the Warrant Stock issuable upon exercise of this Warrant Agreement and the
Common Stock issuable upon conversion of the Warrant Stock are not registered under the 1933 Act or qualified under applicable state securities laws on the ground that the issuance contemplated by this

  
 6 

	 	 
Warrant Agreement will be exempt from the registration and qualifications requirements thereof, and (ii) that Your reliance on such exemption is predicated on the representations set forth
in this Section 7. 

  

	 	•	 	 Disposition of Our Rights. In no event will We make a disposition of any of Our rights to acquire Warrant Stock or Warrant Stock issuable upon
exercise of such rights or the Common Stock issuable upon conversion of the Warrant Stock unless and until (i) We shall have notified You in writing of the proposed disposition, and (ii) the transferee agrees to be bound in writing to the
applicable terms and conditions of this Warrant Agreement, and (iii) if You request, We shall have furnished You with an opinion of counsel satisfactory to You and Your counsel to the effect that (A) appropriate action necessary for
compliance with the 1933 Act has been taken, or (B) an exemption from the registration requirements of the 1933 Act is available. Notwithstanding the foregoing, the restrictions imposed upon the transferability of any of Our rights to acquire
Warrant Stock or Warrant Stock issuable on the exercise of such rights or the Common Stock issuable upon conversion of the Warrant Stock do not apply to transfers from the beneficial owner of any of the aforementioned securities to its nominee or
from such nominee to its beneficial owner, and shall terminate as to any particular share of Warrant Stock when (1) such security shall have been effectively registered under the 1933 Act and sold by the holder thereof in accordance with such
registration or (2) such security shall have been sold without registration in compliance with Rule 144 under the 1933 Act, or (3) a letter shall have been issued to You at Our request by the staff of the Securities and Exchange Commission
or a ruling shall have been issued to You at Our request by such Commission stating that no action shall be recommended by such staff or taken by such Commission, as the case may be, if such security is transferred without registration under the
1933 Act in accordance with the conditions set forth in such letter or ruling and such letter or ruling specifies that no subsequent restrictions on transfer are required. Whenever the restrictions imposed hereunder shall terminate, as hereinabove
provided, the holder of a share of Warrant Stock then outstanding as to which such restrictions have terminated shall be entitled to receive from You, without expense to such holder, one or more new certificates for the Warrant or for such shares of
Warrant Stock not bearing any restrictive legend referring to 1933 Act registration or exemption. Provided no Event of Default (as set forth in the Loan Agreement) has occurred and is continuing, We agree not to transfer this Warrant Agreement to
any of Your direct competitors, as determined in good faith by Your Board of Directors. 

  

	 	•	 	 Financial Risk. We have such knowledge and experience in financial and business matters and knowledge of Your business affairs and financial
condition as to be capable of evaluating the merits and risks of Our investment, and have the ability to bear the economic risks of Our investment. 

  

	 	•	 	 Risk of No Registration. We understand that if You do not register with the Securities and Exchange Commission pursuant to Section 12 of
the 1934 Act (the “1934 Act”), or file reports pursuant to Section 15(d), of the 1934 Act, or if a registration statement covering the securities under the 1933 Act is not in effect when We desire to sell (i) the rights to
purchase Warrant Stock pursuant to this Warrant Agreement, or (ii) the Warrant Stock issuable upon exercise of the right to purchase, or (iii) the Common Stock issuable upon conversion of the Warrant Stock, We may be required to hold such
securities for an indefinite period. We also understand that any sale of Our right to purchase Warrant Stock or Warrant Stock or Common Stock issuable upon conversion of the Warrant Stock, which might be made by it in reliance upon Rule 144 under
the 1933 Act may be made only in accordance with the terms and conditions of that Rule. 

  

	 	•	 	 Accredited Investor. We are an “accredited investor” within the meaning of the Securities and Exchange Rule 501 of Regulation D of the
1933 Act, as presently in effect. 

  

	 	•	 	 Lock-Up. We agree that We will not, without the prior written consent of the managing underwriter, during the period commencing on the date of
the final prospectus relating to Your initial public offering and ending on the date specified by You and the managing underwriter (such period not to exceed one hundred eighty (180) days) (or such longer period, not to exceed 34 days after the
expiration of the 180-day period, as the managing underwriter or the Company shall request in order to facilitate compliance with FINRA rules or any successor or similar rule or regulation), (i) lend, offer, pledge, sell, contract to sell, sell
any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase, or otherwise transfer or dispose of, directly or indirectly, any shares of Your common stock or any securities convertible
into or exercisable or exchangeable for Your common stock (other than those included in such registration), or (ii) enter into any swap or other arrangement that transfers to another, in whole or in part, any of the economic consequences of
ownership of Your common stock, whether any such transaction described in clause (i) or (ii) above is to be settled by delivery of Your common stock or other securities, in cash or otherwise. The foregoing provisions of this paragraph
shall apply only to Your initial 

  
 7 

 
offering of equity securities, shall not apply to the sale of any shares to an underwriter pursuant to an underwriting agreement, and shall only be applicable to Us if all officers, directors and
greater than one percent (1%) stockholders of You enter into similar agreements. The underwriters in connection with Your initial public offering are intended third-party beneficiaries of this paragraph and shall have the right, power and
authority to enforce the provisions hereof as though they were a party hereto. We agree to execute such agreements as may be reasonably requested by the underwriters in Your initial public offering that are consistent with this paragraph or that are
necessary to give further effect thereto. 
 In order to enforce the foregoing covenant, You may impose stop-transfer
instructions with respect to Our Warrant Stock (and the shares or securities of every other person subject to the foregoing restriction) until the end of such period. We further agree that a legend reading substantially as follows shall be placed on
all certificates representing all of Our Warrant Stock (and the shares or securities of every other person subject to the restriction contained in this paragraph): 
 THE SECURITIES REPRESENTED BY THIS CERTIFICATE ARE SUBJECT TO A LOCK-UP PERIOD AFTER THE EFFECTIVE DATE OF THE ISSUER’S REGISTRATION STATEMENT FILED UNDER THE ACT, AS AMENDED, AS SET FORTH IN AN
AGREEMENT BETWEEN THE COMPANY AND THE ORIGINAL HOLDER OF THESE SECURITIES, A COPY OF WHICH MAY BE OBTAINED AT THE ISSUER’S PRINCIPAL OFFICE. SUCH LOCK-UP PERIOD IS BINDING ON TRANSFEREES OF THESE SHARES. 

 
  

	8.	NOTICES YOU AGREE TO PROVIDE US. 

 
 You agree to give Us at least ten (10) days
prior written notice of the following events: 
  

	 	•	 	 If You pay a Dividend or distribution declaration upon Your stock. 

 

	 	•	 	 If You offer for subscription pro-rata to all Your existing shareholders additional stock or other rights. 

 

	 	•	 	 If You consummate or sign definitive documents providing for a Merger Event (provided that Your obligation to provide notice regarding the signing of
definitive documents may be subject to confidentiality obligations imposed upon You in connection with such signing). 

  

	 	•	 	 If You have an initial public offering. 

  

	 	•	 	 If You dissolve or liquidate. 

 All notices in this Section must describe the event in reasonable detail, including (as applicable), how the event adjusts either Our number of shares or Our Exercise Price and the method used for such
adjustment. 
 Timely Notice. Your failure to timely provide such notice required above shall entitle Us to retain the benefit of the
applicable notice period notwithstanding anything to the contrary contained in any insufficient notice received by Us. 
  

 

	9.	DOCUMENTS YOU WILL PROVIDE US. 

  

Upon signing this Warrant Agreement You will provide Us with: 

 

	 	•	 	 Executed originals of this Warrant Agreement, and all other documents and instruments that We may reasonably require 

 

	 	•	 	 Secretary’s certificate of incumbency and authority 

 

	 	•	 	 Certified copy of resolutions of Your board of directors approving this Warrant Agreement 

 

	 	•	 	 Certified copy of Certificate of Incorporation and by-laws as amended through the Effective Date 

 

	 	•	 	 Current Investors’ Rights Agreement 

 So long as this Warrant Agreement is in effect, until the consummation of Your initial public offering, You shall provide Us with the following: 

  
 8 

	 	•	 	 Within five (5) Business Days after the final closing of any equity financing, or extension of an existing round of equity financing, occurring
after the Effective Date, in which You issue preferred stock or other securities (other than Your initial public offering) You will provide Us with copies of the fully executed equity financing documents, including without limitation the related
stock purchase agreement, investors rights agreement, voting agreement, amended or restated articles/certificates of incorporation, current capitalization table and other related documents. 

 

	 	•	 	 Upon Our request, You shall provide Us with any 409A Valuation Reports or other similar reports prepared for You. 

 

	 	•	 	 After all obligations under the Loan Agreement have been finally paid in full, upon Our reasonable request, You will provide Us with (1) an
unaudited income statement and an unaudited balance sheet prepared in accordance with GAAP (except for the absence of footnotes and subject to year-end adjustments) accompanied by a report detailing any material contingencies, and (2) within
one hundred eighty (180) days of the end of each fiscal year end, You will provide Us with audited financial statements accompanied by an audit report of the independent certified public accountants. 

 

	 	•	 	 You shall submit to Us any other documents and other information that We may reasonably request from time to time that are necessary to implement the
provisions and purposes of this Warrant Agreement. 

  

 

	10.	REGISTRATION RIGHTS UNDER THE 1933 ACT. 

 
 You agree that, to the extent at any time after
the Effective Date You and Your stockholders amend that certain Amended and Restated Investors’ Rights Agreement, dated as of January 7, 2010 (as amended, the “Investors’ Rights Agreement”), You will undertake commercially
reasonable efforts to ensure that the shares of Your common stock into which the Warrant Stock is convertible shall be granted registration rights thereunder. 
  

 

	11.	OTHER LEGAL PROVISIONS THE PARTIES WILL ABIDE BY. 

 
 Effective Date. This Warrant Agreement
shall be construed and shall be given effect in all respects as if it had been executed and delivered by the Parties on the date hereof. This Warrant Agreement shall be binding upon any of the successors or assigns of the Parties. 

Attorney’s Fees. In any litigation, arbitration or court proceeding between the Parties relating to this Warrant Agreement, the prevailing
party shall be entitled to reasonable attorneys’ fees and expenses and all costs of proceedings incurred in enforcing this Warrant Agreement. 
 Governing Law. This Warrant Agreement shall be governed by and construed for all purposes under and in accordance with the laws of the State of California without giving effect to that body of law
pertaining to conflicts of laws. 
 Consent to Jurisdiction and Venue. All judicial proceedings arising in or under or related to this
Warrant Agreement may be brought in any state or federal court of competent jurisdiction located in the State of California. By execution and delivery of this Warrant Agreement, each party hereto generally and unconditionally; (a) consents to
personal jurisdiction in San Mateo County, State of California; (b) waives any objection as to jurisdiction or venue in San Mateo County, State of California; (c) agrees not to assert any defense based on lack of jurisdiction or venue in
the aforesaid courts; and (d) irrevocably agrees to be bound by any judgment rendered thereby in connection with this Warrant Agreement. Service of process on any party hereto in any action arising out of or relating to this Warrant Agreement
shall be effective if given in accordance with the requirements for notice set forth in this Section, and shall be deemed effective and received as set forth therein. Nothing herein shall affect the right to serve process in any other manner
permitted by law or shall limit the right of either party to bring proceedings in the courts of any other jurisdiction. 
 Mutual Waiver of
Jury Trial; Judicial Reference. Because disputes arising in connection with complex financial transactions are most quickly and economically resolved by an experienced and expert person and the Parties wish applicable state and federal laws to
apply (rather than arbitration rules), The Parties desire that their disputes be resolved by a judge applying such applicable laws. EACH OF THE PARTIES SPECIFICALLY WAIVES ANY RIGHT THEY MAY HAVE TO TRIAL BY JURY OF ANY CAUSE OF ACTION, CLAIM.
CROSS-CLAIM, COUNTERCLAIM, THIRD PARTY CLAIM OR ANY OTHER CLAIM (COLLECTIVELY, “CLAIMS”) ASSERTED BY YOU AGAINST US OR OUR ASSIGNEE OR BY US OR OUR ASSIGNEE AGAINST YOU. IN THE EVENT THAT THE FOREGOING JURY TRIAL WAIVER IS NOT
ENFORCEABLE, ALL CLAIMS, INCLUDING ANY AND ALL QUESTIONS OF LAW OR 

  
 9 

 
FACT RELATING THERETO, SHALL, AT THE WRITTEN REQUEST OF ANY PARTY, BE DETERMINED BY JUDICIAL REFERENCE PURSUANT TO THE CALIFORNIA CODE OF CIVIL PROCEDURE (“REFERENCE”). THE PARTIES
SHALL SELECT A SINGLE NEUTRAL REFEREE, WHO SHALL BE A RETIRED STATE OR FEDERAL JUDGE. IN THE EVENT THAT THE PARTIES CANNOT AGREE UPON A REFEREE, THE REFEREE SHALL BE APPOINTED BY THE COURT. THE REFEREE SHALL REPORT A STATEMENT OF DECISION TO THE
COURT. NOTHING IN THIS SECTION SHALL LIMIT THE RIGHT OF ANY PARTY AT ANY TIME TO EXERCISE LAWFUL SELF-HELP REMEDIES, FORECLOSE AGAINST COLLATERAL OR OBTAIN PROVISIONAL REMEDIES. THE PARTIES SHALL BEAR THE FEES AND EXPENSES OF THE REFEREE EQUALLY
UNLESS THE REFEREE ORDERS OTHERWISE. THE REFEREE SHALL ALSO DETERMINE ALL ISSUES RELATING TO THE APPLICABILITY, INTERPRETATION, AND ENFORCEABILITY OF THIS SECTION. THE PARTIES ACKNOWLEDGE THAT THE CLAIMS WILL NOT BE ADJUDICATED BY A JURY. This
waiver extends to all such Claims, including Claims that involve Persons other than You and Us; Claims that arise out of or are in any way connected to the relationship between You and Us; and any Claims for damages, breach of contract, specific
performance, or any equitable or legal relief of any kind, arising out of this Warrant Agreement. 
 Counterparts. This Warrant Agreement
may be executed in two or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument. 
 Notices. Any notice required or permitted under this Warrant Agreement shall be given in writing and shall be deemed effectively given upon the earlier of (1) actual receipt or 3 days after
mailing if mailed postage prepaid by regular or airmail to Us or You or (2) one day after it is sent by overnight mail via nationally recognized courier or (3) on the same day as sent via confirmed facsimile transmission, provided that the
original is sent by personal delivery or mail by the sending party. 
 Remedies. In the event of any default hereunder, the
non-defaulting party may proceed to protect and enforce its rights either by suit in equity and/or by action at law, including but not limited to an action for damages as a result of any such default, and/or an action for specific performance for
any default where such party will not have an adequate remedy at law and where damages will not be readily ascertainable. Each party expressly acknowledges and agrees that there is no adequate remedy at law for any breach of this Warrant Agreement
and that in the event of any breach of this Warrant Agreement, the injured party shall be entitled to specific performance of any or all provisions hereof or an injunction prohibiting the other party from continuing to commit any such breach of this
Warrant Agreement. 
 Survival. The representations, warranties, covenants, and conditions of the Parties contained herein or made
pursuant to this Warrant Agreement shall survive the execution and delivery of this Warrant Agreement. 
 Severability. In the event any
one or more of the provisions of this Warrant Agreement shall for any reason be held invalid, illegal or unenforceable, the remaining provisions of this Warrant Agreement shall be unimpaired, and the invalid, illegal or unenforceable provision shall
be replaced by a mutually acceptable valid, legal and enforceable provision, which comes closest to the intention of the Parties underlying the invalid, illegal or unenforceable provision. 
 Entire Agreement. This Warrant Agreement constitutes the entire agreement between the Parties pertaining to the subject matter contained in it and supersedes all prior and contemporaneous
agreements, representations and undertakings of the Parties, whether oral or written, with respect to such subject matter. 
 Amendments.
Any provision of this Warrant Agreement may only be amended by a written instrument signed by the Parties. 
 Lost Warrants or Stock
Certificates. You covenant to Us that, upon receipt of evidence reasonably satisfactory to Us of the loss, theft, destruction or mutilation of this Warrant Agreement or any stock certificate and, in the case of any such loss, theft or
destruction, upon receipt of an indemnity reasonably satisfactory to You, or in the case of any such mutilation upon surrender and cancellation of such Warrant Agreement or stock certificate, You will make and deliver a new Warrant Agreement or
stock certificate, of like tenor, in lieu of the lost, stolen, destroyed or mutilated Warrant Agreement or stock certificate. 

  
 10 

 Rights as Stockholders. We shall not, as a party to this Warrant Agreement, be entitled to vote or
receive dividends or be deemed the holder of Series D Preferred Stock or any of Your other securities which may at any time be issuable upon the exercise hereof for any purpose, nor shall anything contained herein be construed to confer upon Us any
of the rights of one of Your stockholders or any right to vote for the election of directors or upon any matter submitted to stockholders at any meeting thereof, or to receive dividends or subscription rights or otherwise until this Warrant
Agreement is exercised and the shares purchasable upon the exercise hereof shall have become deliverable, as provided herein. 
 Facsimile
Signatures. This Warrant Agreement may be executed and delivered by facsimile and upon such delivery the facsimile signature will be deemed to have the same effect as if the original signature had been delivered to the other party. 

(Signature Page to Follow) 

  
 11 

 IN WITNESS WHEREOF, each of the Parties have caused this Warrant Agreement to be executed by its
officers who are duly authorized as of the Effective Date. 
  

			
	You:	 	VIOLIN MEMORY, INC.
		
	Signature:	 	 /s/ Donald Basile

		
	Print Name:	 	Donald Basile
		
	Title:	 	President and CEO
		
	Us:	 	TRIPLEPOINT CAPITAL LLC
		
	Signature:	 	 /s/ Sajal Srivastava

		
	Print Name:	 	 Sajal Srivastava

		
	Title:	 	 Chief Operating Officer

 [SIGNATURE PAGE TO WARRANT AGREEMENT 0803-W-01] 

  
 12 

 EXHIBIT I 
 NOTICE OF EXERCISE 
  

	To:	[                           
 ] 

  

	1.	We hereby elect to purchase [                ] shares of the Series
[            ] Preferred Stock of [                    ], pursuant to the terms of the
Plain English Warrant Agreement dated the [    ] day of [            ], [20    ] (the “Plain English Warrant Agreement”) between You and
Us, We hereby tender here payment of the purchase price for such shares in full, together with all applicable transfer taxes, if any. 

  

	2.	Method of Exercise (Please initial the applicable blank) 

  

	 	a.	                    The undersigned elects to exercise the Plain
English Warrant Agreement by means of a cash payment, and gives You full payment for the purchase price of the shares being purchased, together with all applicable transfer taxes, if any. 

 

	 	b.	                    The undersigned elects to exercise the Plain
English Warrant Agreement by means of the Net Issuance Exercise method of Section 3 of the Plain English Warrant Agreement. 

  

	3.	In exercising Our rights to purchase the Series [            ] Preferred Stock of
[                    ], We hereby confirm and acknowledge the investment representations, warranties and covenants made in Section 7 of the
Plain English Warrant Agreement. 

 Please issue a certificate or certificates representing these purchased shares of Series
[            ] Preferred Stock in Our name or in such other name as is specified below. 
  

			
		 	  

		 	(Name)
		
	            	 	  

		 	(Address)

					
			
		 	US:	 	TRIPLEPOINT CAPITAL LLC
			
	            	 	By:	 	  

			
		 	Title:	 	  

			
		 	Date:	 	  

  
 13 

 EXHIBIT II 
 ACKNOWLEDGMENT OF EXERCISE 

[                         
   ], hereby acknowledges receipt of the “Notice of Exercise” from TRIPLEPOINT CAPITAL LLC, to purchase [                ] shares of the Series
[            ] Preferred Stock of [                    ], pursuant to the terms of the
Plain English Warrant Agreement, and further acknowledges that [            ] shares remain subject to purchase under the terms of the Plain English Warrant Agreement. 

 

							
	 YOU:
	 		 	VIOLIN MEMORY, INC.
				
		 		 	By:	 	  

				
		 		 	Title:	 	  

				
		 		 	Date:	 	  

  
 14 

 EXHIBIT III 
 TRANSFER NOTICE 
 FOR VALUE RECEIVED, the foregoing Plain English Warrant Agreement
and all rights evidenced thereby are hereby transferred and assigned to 
  

                         
                                         
                                         
                  
 (Please Print) 

Whose address is
                                         
                                         
                                         
                  
  
                                  
                                         
                                         
                                         
                  
  

							
	Dated:	 	  
	 		 	
				
	Holder’s Signature:	 	  
	 		 	
				
	Holder’s Address:	 	  
	 		 	
				
	Transferee’s Signature:	 	  
	 		 	
				
	Transferee’s Address:	 	  
	 		 	
				
	Signature Guaranteed:	 	  
	 		 	

 NOTE: The signature to this Transfer Notice must correspond with the name as it appears on the face of the Plain
English Warrant Agreement, without alteration or enlargement or any change whatever. Officers of corporations and those acting in a fiduciary or other representative capacity should file proper evidence of authority to assign the foregoing Plain
English Warrant Agreement. 

  
 15EX-4.6

 Exhibit 4.6 
 THIS NOTE AND THE SECURITIES ISSUABLE UPON THE CONVERSION HEREOF HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED. THEY MAY NOT BE SOLD, OFFERED FOR SALE, PLEDGED, HYPOTHECATED, OR
OTHERWISE TRANSFERRED EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR AN OPINION OF COUNSEL SATISFACTORY TO THE COMPANY THAT REGISTRATION IS NOT REQUIRED UNDER SUCH ACT OR UNLESS SOLD PURSUANT
TO RULE 144 UNDER SUCH ACT. 
 CONVERTIBLE SUBORDINATED PROMISSORY NOTE 

 

			
	No. [2013-      ]	  	Date of Issuance
		
	 $[            ]
	  	June [    ], 2013

 FOR VALUE RECEIVED Violin Memory, Inc., a Delaware corporation (the “Company”), hereby promises
to pay the order of [                        ] (the “Lender”), the principal sum of
[                        ] dollars ($[            ]), together with
interest thereon from the date of this Note. Interest shall accrue at a rate of ten percent (10%) per annum, simple interest. Unless earlier converted into Conversion Shares pursuant to Section 2.2 of that certain Note and Warrant Purchase
Agreement dated June 17, 2013 among the Company, Lender and certain other investors (the “Purchase Agreement”), the principal and accrued interest shall be due and payable by the Company on demand at any time after the Maturity Date
or as otherwise provided under the Purchase Agreement. 
 This Note is one of a series of Notes issued pursuant to the Purchase
Agreement, and capitalized terms not defined herein shall have the meaning set forth in the Purchase Agreement. 
 THIS NOTE IS SUBJECT TO THE
TERMS OF ONE OR MORE SUBORDINATION AGREEMENTS (THE “SUBORDINATION AGREEMENTS”), BY AND AMONG THE COMPANY, TRIPLEPOINT CAPITAL LLC AND/OR OTHER INSTITUTIONAL LENDERS (AS DEFINED IN THE PURCHASE AGREEMENT) AND THE PURCHASERS OF CONVERTIBLE
PROMISSORY NOTES ISSUED UNDER THE PURCHASE AGREEMENT PURSUANT TO WHICH THE COMPANY’S OBLIGATIONS HEREUNDER ARE SUBORDINATED IN FULL TO THE COMPANY’S OBLIGATIONS TO THE INSTITUTIONAL LENDERS, WHETHER EXISTING ON THE DATE HEREOF OR HEREAFTER
ARISING. 
 1. Payment. All payments shall be made in lawful money of the United States of America at the principal office of
the Company, or at such other place as the holder hereof may from time to time designate in writing to the Company. Payment shall be credited first to Costs (as defined below), if any, then to accrued interest due and payable and any remainder
applied to principal. Subject to the terms the Subordination Agreements, prepayment of principal, together with accrued interest, may be made without the Lender’s consent upon ten (10) days’ prior written notice to the holder hereof.
The Company hereby waives demand, notice, presentment, protest and notice of dishonor. 

 2. Security. This Note is a general unsecured obligation of the Company. 

3. Priority. This Note is subordinated in right of payment to all indebtedness of the Company to the Institutional Lenders pursuant to
the terms of the Subordination Agreements. 
 4. Conversion of the Notes. This Note and any amounts due hereunder shall be
convertible into Conversion Shares in accordance with the terms of Section 2.2 of the Purchase Agreement. As promptly as practicable after the conversion of this Note, the Company at its expense shall issue and deliver to the holder of this
Note, upon surrender of the Note, a certificate or certificates for the number of full Conversion Shares issuable upon such conversion. 
 5. Amendments and Waivers; Resolutions of Dispute; Notice. The amendment or waiver of any term of this Note, the resolution of any controversy or claim arising out of or relating to this Note and the
provision of notice shall be conducted pursuant to the terms of the Purchase Agreement. 
 6. Successors and Assigns. This Note
applies to, inures to the benefit of, and binds the successors and assigns of the parties hereto. Any transfer of this Note may be effected only pursuant to the Purchase Agreement. 

7. Officers and Directors not Liable. In no event shall any officer or director of the Company be liable for any amounts due and payable
pursuant to this Note. 
 8. Expenses. The Company hereby agrees, subject only to any limitation imposed by applicable law, to
pay all expenses, including reasonable attorneys’ fees and legal expenses, incurred by the holder of this Note in endeavoring to collect any amounts payable hereunder which are not paid when due, whether by declaration or otherwise
(“Costs”). The Company agrees that any delay on the part of the holder in exercising any rights hereunder will not operate as a waiver of such rights. The holder of this Note shall not by any act, delay, omission or otherwise be deemed to
have waived any of its rights or remedies, and no waiver of any kind shall be valid unless, in writing and signed by the party or parties waiving such rights or remedies. 
 9. Governing Law. This Note shall be governed by and construed under the laws of the State of Delaware as applied to other instruments made by Delaware residents to be performed entirely within the State
of Delaware. 
 10. Approval. The Company hereby represents that its board of directors, in the exercise of its fiduciary duty,
has approved the Company’s execution of this Convertible Subordinated Promissory Note based upon a reasonable belief that the principal provided hereunder is appropriate for the Company after reasonable inquiry concerning the Company’s
financing objectives and financial situation. 

			
	VIOLIN MEMORY, INC.
		
	By:	 	 
		 	 Donald G. Basile
 President and
Chief Executive Officer

 [Signature Page to Violin Memory, Inc. Promissory Note]

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00220-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00220-of-00352.parquet"}]]